Genomic selection for carrier-state resistance in chicken commercial lines

BMC Proceedings

Proceedings

Catherine Beaumont¹  Fanny Calenge¹  Andres Legarra² 

[1] INRA UMR83 Unité de Recherches Avicoles, 37380, Nouzilly, France;INRA UR0631 Station d’Amélioration Génétique des Animaux, chemin de Borde-Rouge, 31326, Auzeville, France;

关键词: Variance Component;    Genomic Selection;    Genetic Evaluation;    Commercial Line;    Theoretical Accuracy;   

DOI  :  10.1186/1753-6561-5-S4-S24

来源: Springer

【 摘 要 】

BackgroundSalmonella propagation by apparently healthy chicken and subsequent food security concerns could be decreased by the selection and use of chicken lines more resistant to carrier-state. In the present study we applied the first steps of the genomic selection methodology to assess the interest of including genetic markers for the genetic evaluation of hen lines infected with Salmonella Enteritidis.MethodsWe studied commercial laying hen lines divergently selected for resistance to Salmonella carrier-state at two different ages. A total of 600 animals were typed with 1536 SNP markers and artificially infected with S. Enteritidis. Phenotypes were collected four weeks (young animals) or five weeks (adults) later. Two types of variance component analyses, including or not including SNP data, were performed and compared. All variance components were estimated by Bayesian methods and Gibbs sampling.ResultsThe comparison of both genetic analyses shows that SNP are efficient in capturing genetic variation, although none of them captures a large affect on the traits studied. Average accuracies do not change between analyses, showing that using SNP data does not really increase information.ConclusionsThese preliminary results show that genomic selection for Salmonella carrier-state resistance in laying hens is promising, although a denser SNP coverage of the genome on a higher number of animals is needed to assess its feasibility and efficiency compared to classical pedigree evaluation.

【 授权许可】

CC BY   
© Calenge et al; licensee BioMed Central Ltd. 2011